

<p>86-166654/26 805 ONOY 22.10.84 ONO PHARMACEUTICAL KK *J6 1100-518-A 22.10.84-JP-220565 (19.05.86) A61k-09 A61k-31/19 A61k-37/22 C07d-405/04 Lyophilised liposome compsn. - contg. di:myristoyl phosphatidyl choline as main component C86-071641</p>	<p>B(1-D2, 4-B1B, 4-B2E, 4-B4F, 5-B1P, 6-A2, 10-A7, 12-M11F) 8</p>
<p>Liposome prepn. has dimyristoylphosphatidyl choline (1) as principal component of liposome membrane material, and contains an arachidonic acid metabolite (or its structurally related deriv., its synthetase inhibitor or its antagonist) as active ingredient. Further saccharides are added, and the mixt. is lyophilized. USE/ADVANTAGE The liposome prepn. can be stored in a refrigerator or, at room temp., and in use, redispersed in distilled H₂O or saline or transfusion for injection. As (1) is used as principal membrane material, partition coefficient between aq. phase and liposome membrane shows maximum value 100-5000. At redispersion, a homogeneous dispersion is easily prepared by slight shaking with a little bubbling.</p>	<p>Particle size of liposome is 0.5-5.0 μm (peak of vol. distri- bution), which is suitable for intravenous injection. MATERIALS Arachidonic acid metabolite is e.g. prostaglandin, prosta- cyclin, thromboxane or leukotriene. Structurally related cpd. is e.g. 6-keto-PGE deriv., carbacycline deriv. or PGD₂ deriv. Saccharide is esp. lactose or mannitol. The liposome membrane contains further neutral lipid or charged lipid. Neutral lipid is esp. cholesterol or triglyceride. (8ppW105DAHDwgNo0/2).</p> <p style="text-align: right;">J61100518-A</p>

Best Available Copy